Search

Your search keyword '"Zampino, Rosa"' showing total 548 results
Start Over Author "Zampino, Rosa"
548 results on '"Zampino, Rosa"'

6. WED-414 Demographic, virological and clinical features of patients with chronic hepatitis delta treated with bulevirtide: a multicenter italian study (d-shield)

Author

Anolli, Maria Paola, primary, Degasperi, Elisabetta, additional, D'Offizi, Giampiero, additional, Rianda, Alessia, additional, Loglio, Alessandro, additional, Viganò, Mauro, additional, Ciancio, Alessia, additional, Troshina, Yulia, additional, Brunetto, Maurizia, additional, Coco, Barbara, additional, Zaltron, Serena, additional, Toniutto, Pierluigi, additional, Marinaro, Letizia, additional, Gori, Andrea, additional, Federico, Alessandro, additional, Santantonio, Teresa, additional, Verucchi, Gabriella, additional, Morisco, Filomena, additional, Mangia, Alessandra, additional, De Nicola, Stella, additional, Maracci, Monia, additional, Romano, Antonietta, additional, Gatti, Pietro, additional, Zampino, Rosa, additional, Persico, Marcello, additional, Pozzoni, Pietro, additional, Pellicelli, Adriano, additional, Coppola, Nicola, additional, Pileri, Francesca, additional, Tonnini, Matteo, additional, Puoti, Massimo, additional, and Lampertico, Pietro, additional

Published
2024
Full Text
View/download PDF

7. In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections

Author

Paul, Mical, Benattar, Yael Dishon, Dickstein, Yaakov, Bitterman, Roni, Zayyad, Hiba, Koppel, Fidi, Zak-Doron, Yael, Altunin, Sergey, Andria, Nizar, Neuberger, Ami, Stern, Anat, Petersiel, Neta, Raines, Marina, Karban, Amir, Leibovici, Leonard, Yahav, Dafna, Eliakim-Raz, Noa, Zusman, Oren, Elbaz, Michal, Atamna, Heyam, Daitch, Vered, Babich, Tanya, Carmeli, Yehuda, Nutman, Amir, Adler, Amos, Levi, Inbar, Daikos, George L., Skiada, Anna, Pavleas, Ioannis, Antoniadou, Anastasia, Kotsaki, Antigoni, Durante-Mangoni, Emanuele, Andini, Roberto, Iossa, Domenico, Bernardo, Mariano, Cavezza, Giusi, Bertolino, Lorenzo, Giuffre, Giuseppe, Giurazza, Roberto, Ruocco, Giuseppe, Galdo, Maria, Murino, Patrizia, Cristinziano, Adriano, Corcione, Antonio, Zampino, Rosa, Mouton, Johan, Friberg, Lena, Theuretzbacher, Ursula, Temkin, Elizabeth, Lellouche, Jonathan, Rakovitsky, Nadya, Hameir, Amichay, Daikos, George, Dishon, Yael, Eliakim, Noa, and Friberg, Lena E.

Published
2022
Full Text
View/download PDF

9. Viral Hepatitis C

Author

Adinolfi, Luigi Elio, Mangoni, Emanuele Durante, Marrone, Aldo, Zampino, Rosa, Rinaldi, Luca, Radu-Ionita, Florentina, editor, Pyrsopoulos, Nikolaos T., editor, Jinga, Mariana, editor, Tintoiu, Ion C., editor, Sun, Zhonghua, editor, and Bontas, Ecaterina, editor

Published
2020
Full Text
View/download PDF

10. Cardiac sequelae after coronavirus disease 2019 recovery: a systematic review

Author

Durante-Mangoni, Emanuele, Iossa, Domenico, Bertolino, Lorenzo, Ursi, Maria Paola, D'Amico, Fabiana, Karruli, Arta, Ramadan, Mohammad, Andini, Roberto, Zampino, Rosa, Bernardo, Mariano, Ruocco, Giuseppe, Dialetto, Giovanni, Covino, Franco Enrico, Manduca, Sabrina, Della Corte, Alessandro, De Feo, Marisa, De Vivo, Stefano, De Rimini, Maria Luisa, Galdieri, Nicola, and Ramadan, Mohammad Said

Published
2021
Full Text
View/download PDF

13. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes

Author

Paul, Mical, Benattar, Yael Dishon, Dickstein, Yaakov, Bitterman, Roni, Zayyad, Hiba, Koppel, Fidi, Zak-Doron, Yael, Altunin, Sergey, Andria, Nizar, Neuberger, Ami, Stern, Anat, Petersiel, Neta, Raines, Marina, Karban, Amir, Leibovici, Leonard, Yahav, Dafna, Eliakim-Raz, Noa, Zusman, Oren, Elbaz, Michal, Atamna, Heyam, Daitch, Vered, Babich, Tanya, Carmeli, Yehuda, Nutman, Amir, Adler, Amos, Levi, Inbar, Daikos, George L., Skiada, Anna, Pavleas, Ioannis, Antoniadou, Anastasia, Kotsaki, Antigoni, Durante-Mangoni, Emanuele, Andini, Roberto, Iossa, Domenico, Bernardo, Mariano, Cavezza, Giusi, Bertolino, Lorenzo, Giuffre, Giuseppe, Giurazza, Roberto, Cuccurullo, Susanna, Galdo, Maria, Murino, Patrizia, Cristinziano, Adriano, Corcione, Antonio, Zampino, Rosa, Pafundi, Pia Clara, Mouton, Johan, Friberg, Lena, Kristoffersson, Anders, Theuretzbacher, Ursula, Lellouche, Jonathan, Temkin, Elizabeth, Daikos, George, Dishon-Benattar, Yael, Friberg, Lena E., and Mouton, Johan W.

Published
2020
Full Text
View/download PDF

14. Leadless Pacemaker Infection Risk in Patients with Cardiac Implantable Electronic Device Infections: A Case Series and Literature Review

Author

Bertolino, Lorenzo, primary, Florio, Letizia Lucia, additional, Patauner, Fabian, additional, Gallo, Raffaella, additional, Peluso, Anna Maria, additional, Scafuri, Antonio, additional, De Vivo, Stefano, additional, Corrado, Carmelina, additional, Zampino, Rosa, additional, Ruocco, Giuseppe, additional, D’Onofrio, Antonio, additional, and Durante-Mangoni, Emanuele, additional

Published
2023
Full Text
View/download PDF

16. Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity

Author

Daitch, Vered, Paul, Mical, Daikos, George L., Durante-Mangoni, Emanuele, Yahav, Dafna, Carmeli, Yehuda, Benattar, Yael Dishon, Skiada, Anna, Andini, Roberto, Eliakim-Raz, Noa, Nutman, Amir, Zusman, Oren, Antoniadou, Anastasia, Cavezza, Giusi, Adler, Amos, Dickstein, Yaakov, Pavleas, Ioannis, Zampino, Rosa, Bitterman, Roni, Zayyad, Hiba, Koppel, Fidi, Zak-Doron, Yael, Levi, Inbar, Babich, Tanya, Turjeman, Adi, Ben-Zvi, Haim, Friberg, Lena E., Mouton, Johan W., Theuretzbacher, Ursula, and Leibovici, Leonard

Published
2021
Full Text
View/download PDF

18. Clinical results with the use of ceftaroline and ceftobiprole: real-life experience in a tertiary care hospital

Author

Zampino, Rosa, primary, Gallo, Raffaella, additional, Salemme, Anna, additional, Marrazzo, Tommaso, additional, Iossa, Domenico, additional, Karruli, Arta, additional, Andini, Roberto, additional, Esitini, Daniele, additional, Moretto, Simona Maria, additional, De Gregorio, Fabrizio, additional, and Durante-Mangoni, Emanuele, additional

Published
2023
Full Text
View/download PDF

20. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

Author

Paul, Mical, Daikos, George L, Durante-Mangoni, Emanuele, Yahav, Dafna, Carmeli, Yehuda, Benattar, Yael Dishon, Skiada, Anna, Andini, Roberto, Eliakim-Raz, Noa, Nutman, Amir, Zusman, Oren, Antoniadou, Anastasia, Pafundi, Pia Clara, Adler, Amos, Dickstein, Yaakov, Pavleas, Ioannis, Zampino, Rosa, Daitch, Vered, Bitterman, Roni, Zayyad, Hiba, Koppel, Fidi, Levi, Inbar, Babich, Tanya, Friberg, Lena E, Mouton, Johan W, Theuretzbacher, Ursula, and Leibovici, Leonard

Published
2018
Full Text
View/download PDF

26. Prevalence and Clinical Consequences of Colistin Heteroresistance and Evolution into Full Resistance in Carbapenem-Resistant Acinetobacter baumannii

Author

Kon, Hadas, primary, Hameir, Amichay, additional, Nutman, Amir, additional, Temkin, Elizabeth, additional, Keren Paz, Alona, additional, Lellouche, Jonathan, additional, Schwartz, David, additional, Weiss, David S., additional, Kaye, Keith S., additional, Daikos, George L., additional, Skiada, Anna, additional, Durante-Mangoni, Emanuele, additional, Dishon Benattar, Yael, additional, Yahav, Dafna, additional, Daitch, Vered, additional, Bernardo, Mariano, additional, Iossa, Domenico, additional, Friberg, Lena E., additional, Theuretzbacher, Ursula, additional, Leibovici, Leonard, additional, Dickstein, Yaakov, additional, Pollak, Dina, additional, Mendelsohn, Sigal, additional, Paul, Mical, additional, Carmeli, Yehuda, additional, Bitterman, Roni, additional, Zayyad, Hiba, additional, Koppel, Fidi, additional, Zak-Doron, Yael, additional, Altunin, Sergey, additional, Andria, Nizar, additional, Neuberger, Ami, additional, Stern, Anat, additional, Petersiel, Neta, additional, Raines, Marina, additional, Karban, Amir, additional, Eliakim-Raz, Noa, additional, Zusman, Oren, additional, Elbaz, Michal, additional, Atamna, Heyam, additional, Babich, Tanya, additional, Adler, Amos, additional, Levi, Inbar, additional, Pavleas, Ioannis, additional, Antoniadou, Anastasia, additional, Kotsaki, Antigoni, additional, Andini, Roberto, additional, Cavezza, Giusi, additional, Bertolino, Lorenzo, additional, Giuffre, Giuseppe, additional, Giurazza, Roberto, additional, Ruocco, Giuseppe, additional, Galdo, Maria, additional, Murino, Patrizia, additional, Cristinziano, Adriano, additional, Corcione, Antonio, additional, Zampino, Rosa, additional, Mouton, Johan, additional, and Friberg, Lena, additional

Published
2023
Full Text
View/download PDF

30. PNPLA3 and HSD17B13 Polymorphisms’ Influence on Liver Fibrosis Development in a Small Cohort of Italian Patients With Viral Hepatitis

Author

Zampino, Rosa, primary, Coppola, Nicola, additional, Cirillo, Grazia, additional, Iossa, Domenico, additional, Starace, Mario, additional, Marrone, Aldo, additional, Vitrone, Martina, additional, De Pascalis, Stefania, additional, Macera, Margherita, additional, Improta, Marta, additional, Adinolfi, Luigi Elio, additional, Durante-Mangoni, Emanuele, additional, and Miraglia del Giudice, Emanuele, additional

Published
2023
Full Text
View/download PDF

33. Infective endocarditis involving MitraClip© devices: a systematic literature review.

Author

Bertolino, Lorenzo, Ramadan, Mohammad Said, Zampino, Rosa, and Durante-Mangoni, Emanuele

Subjects
MITRAL valve insufficiency, ONLINE information services, MEDICAL information storage & retrieval systems, FEVER, SYSTEMATIC reviews, INFECTIVE endocarditis, INFECTION, HOSPITAL mortality, PROSTHETIC heart valves, STAPHYLOCOCCUS aureus, RESEARCH funding, MEDLINE, COMPLICATIONS of prosthesis, SYMPTOMS
Abstract

Purpose: Progress of interventional cardiology has boosted the use of newer cardiac devices. These devices are perceived to be less prone to infections compared to traditional surgical prostheses, but little data are currently available. In this systematic review (SR), we summarize current literature regarding the clinical characteristics, management, and outcomes of patients with MitraClip-related infective endocarditis (IE). Methods: We conducted a SR of PubMed, Google Scholar, Embase, and Scopus between January 2003 and March 2022. MitraClip-related IE was defined according to 2015 ESC criteria whereas MitraClip involvement as vegetation on the device or on the mitral valve. Risk of bias was assessed through standardized checklist and potential bias of underestimation cannot be excluded. Data regarding clinical presentation, echocardiography, management, and outcome were collected. Results: Twenty-six cases of MitraClip-related IE were retrieved. The median age of patients was 76 [61–83] years with a median EuroScore of 41%. Fever was present in 65.8% of patients followed by signs and symptoms of heart failure (42.3%). IE occurred early in 20 (76.9%) cases with a median time between MitraClip implantation and IE symptom onset of 5 [2–16] months. Staphylococcus aureus was the major causative microorganism (46%). Surgical mitral valve replacement was needed in 50% of patients. A conservative medical approach was considered in the remainder. The overall in-hospital mortality rate was 50% (surgical group: 38.4%; medical group: 58.3%; p = 0.433). Conclusion: Our results suggest that MitraClip-related IE affects elderly, comorbid patients, is mostly due to Staphylococcus aureus, and has a poor prognosis irrespective of the therapeutic approach. Clinicians must be aware of the features of this new entity among cardiovascular infections. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19

Author

Albisinni, Rosina, Vitrone, Martina, Ursi, Maria P, Spiezia, Serenella, Salemme, Anna, Florio, Letizia L, Boccia, Filomena, Iossa, Domenico, Zampino, Rosa, Atripaldi, Luigi, Squillante, Francesco, Maturo, Nicola, Fraganza, Fiorentino, Severino, Sergio, Punzi, Rodolfo, Fiorentino, Giuseppe, Albisinni, Rosina, Vitrone, Martina, Ursi, Maria P, Spiezia, Serenella, Salemme, Anna, Florio, Letizia L, Boccia, Filomena, Iossa, Domenico, Zampino, Rosa, Atripaldi, Luigi, Squillante, Francesco, Maturo, Nicola, Fraganza, Fiorentino, Severino, Sergio, Punzi, Rodolfo, and Fiorentino, Giuseppe

Subjects
Male, SARS-CoV-2, Humans, COVID-19, Anticoagulants, Thrombosis, Hemorrhage, Enoxaparin, Hemostasis and Thrombosis: Original article, Aged, COVID-19 Drug Treatment
Abstract

Background: Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), increases thrombotic risk in hospitalised patients. The rate of thrombosis in patients with COVID-19 is unclear. The role of heparin, frequently used in the management of hospitalised patients, also needs to be clarified. In this study, we investigated the efficacy and safety of enoxaparin given at prophylactic or therapeutic dose in hospitalised patients with COVID-19, and evaluated its role in the development of disease in terms of mortality, and incidence of thrombotic and bleeding events. Material and methods: We included 141 patients with SARS-CoV-2 infection, admitted to five different wards (one intensive care unit, 2 sub-intensive care units, and 2 general infectious disease units) of Cotugno Hospital, a tertiary care hospital in Naples, Italy, between March and May 2020. Results: Over a median time of 17 days (IQR 11-25), enoxaparin was given to 90/141 patients (63.8%) of whom 65 took a prophylactic and 25 a therapeutic dose. We documented 14 episodes of thrombosis (9.9%); almost all were cases of pulmonary embolism. No significant difference in terms of thromboembolic prevention was found between those patients not receiving anticoagulants and those on prophylactic or therapeutic dose of enoxaparin. Five episodes of major bleeding occurred (3.5%); therapeutic dose of enoxaparin was associated with a greater bleeding risk than prophylactic dose (p=0.002). During follow-up, 31 patients (22%) died; these were mostly elderly men with two or more comorbidities at admission. No advantages of enoxaparin, either as prophylaxis or at high doses, in terms of mortality were observed. At multivariate analysis, low estimated glomerular filtration rate, and high total bilirubin and fasting hyperglycaemia were independently associated with a higher mortality. Discussion: We did not observe advantages in terms of either thromboembolic prevention or mortality of enoxaparin, which however was more frequently used in patients with more severe disease. Prophylactic enoxaparin was not seen to be associated with bleeding risk.

Published
2021

43. In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections

Author

Nutman, Amir, primary, Temkin, Elizabeth, additional, Lellouche, Jonathan, additional, Rakovitsky, Nadya, additional, Hameir, Amichay, additional, Daikos, George, additional, Durante-Mangoni, Emanuele, additional, Pavleas, Ioannis, additional, Dishon, Yael, additional, Petersiel, Neta, additional, Yahav, Dafna, additional, Eliakim, Noa, additional, Bernardo, Mariano, additional, Iossa, Domenico, additional, Friberg, Lena E., additional, Theuretzbacher, Ursula, additional, Leibovici, Leonard, additional, Paul, Mical, additional, Carmeli, Yehuda, additional, Benattar, Yael Dishon, additional, Dickstein, Yaakov, additional, Bitterman, Roni, additional, Zayyad, Hiba, additional, Koppel, Fidi, additional, Zak-Doron, Yael, additional, Altunin, Sergey, additional, Andria, Nizar, additional, Neuberger, Ami, additional, Stern, Anat, additional, Raines, Marina, additional, Karban, Amir, additional, Eliakim-Raz, Noa, additional, Zusman, Oren, additional, Elbaz, Michal, additional, Atamna, Heyam, additional, Daitch, Vered, additional, Babich, Tanya, additional, Nutman, Amir, additional, Adler, Amos, additional, Levi, Inbar, additional, Daikos, George L., additional, Skiada, Anna, additional, Antoniadou, Anastasia, additional, Kotsaki, Antigoni, additional, Andini, Roberto, additional, Cavezza, Giusi, additional, Bertolino, Lorenzo, additional, Giuffre, Giuseppe, additional, Giurazza, Roberto, additional, Ruocco, Giuseppe, additional, Galdo, Maria, additional, Murino, Patrizia, additional, Cristinziano, Adriano, additional, Corcione, Antonio, additional, Zampino, Rosa, additional, Mouton, Johan, additional, and Friberg, Lena, additional

Published
2022
Full Text
View/download PDF

45. Long-Term Outcome of Infective Endocarditis Involving Cardiac Implantable Electronic Devices: Impact of Comorbidities and Lead Extraction.

Author

Durante-Mangoni, Emanuele, Ursi, Maria Paola, Andini, Roberto, Mattucci, Irene, Della Ratta, Ester E., Iossa, Domenico, Bertolino, Lorenzo, De Vivo, Stefano, Manduca, Sabrina, Torella, Michele, De Feo, Marisa, and Zampino, Rosa

Subjects
INFECTIVE endocarditis, ELECTRONIC equipment, HOSPITAL mortality, TRICUSPID valve, SURVIVAL rate, CARDIAC surgery, ARTIFICIAL implants
Abstract

(1) Background: Management of cardiac implantable electronic device-related infective endocarditis (CIED-IE) hinges on complete hardware removal. We assessed whether long-term prognosis is affected by device removal, considering baseline patient comorbid conditions; (2) Methods: A total of 125 consecutive patients hospitalized for CIED-IE were included in this retrospective analysis. Outcomes were in-hospital, one-year, and long-term mortality. There were 109 patients who underwent device removal, 91 by transvenous lead extraction (TLE) and 18 by open heart surgery (OHS); (3) Results: TLE translated into lower hospital mortality (4.4% vs. 22.5% with OHS; p = 0.03). Septic pulmonary embolism was the only independent predictor of in-hospital mortality (OR:7.38 [1.49–36.6], p = 0.013). One-year mortality was in contrast independently associated to tricuspid valve involvement (p = 0.01) and Charlson comorbidity index (CCI, p = 0.039), but not the hardware removal modality. After a median follow-up of 41 months, mortality rose to 24%, and was significantly influenced only by CCI. Specifically, patients with a higher CCI who were also treated with TLE showed a survival rate not significantly different from those managed with medical therapy only; (4) Conclusions: In CIED-IE, TLE is the strategy of choice for hardware removal, improving early outcomes. Long-term benefits of TLE are lessened by comorbidities. In cases of CIED-IE with high CCI, a more conservative approach might be an option. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

48. Cardiac sequelae after coronavirus disease 2019 recovery: a systematic review

Author

Ramadan, Mohammad Said, primary, Bertolino, Lorenzo, additional, Zampino, Rosa, additional, Durante-Mangoni, Emanuele, additional, Iossa, Domenico, additional, Ursi, Maria Paola, additional, D'Amico, Fabiana, additional, Karruli, Arta, additional, Ramadan, Mohammad, additional, Andini, Roberto, additional, Bernardo, Mariano, additional, Ruocco, Giuseppe, additional, Dialetto, Giovanni, additional, Covino, Franco Enrico, additional, Manduca, Sabrina, additional, Della Corte, Alessandro, additional, De Feo, Marisa, additional, De Vivo, Stefano, additional, De Rimini, Maria Luisa, additional, and Galdieri, Nicola, additional

Published
2021
Full Text
View/download PDF

49. Multidrug-Resistant Infections and Outcome of Critically Ill Patients with Coronavirus Disease 2019: A Single Center Experience

Author

Karruli, Arta, primary, Boccia, Filomena, additional, Gagliardi, Massimo, additional, Patauner, Fabian, additional, Ursi, Maria Paola, additional, Sommese, Pino, additional, De Rosa, Rosanna, additional, Murino, Patrizia, additional, Ruocco, Giuseppe, additional, Corcione, Antonio, additional, Andini, Roberto, additional, Zampino, Rosa, additional, and Durante-Mangoni, Emanuele, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results